HeartBeam has received a notice of allowance from The United States Patent and Trademark Office for a key patent relating to the initial AI capability for its HeartBeam AIMIGo System.
The patent was entitled “Hand-held device for automatic cardiac risk and diagnostic assessment.”
HeartBeam AIMIGo System is a personal, portable and easy-to-use VECG solution intended to help patients and their clinicians in evaluating cardiac symptoms.
The system employs a reusable, credit card-sized, VECG recording device and cloud-based software to deliver critical data to clinicians in real-time outside of a medical setting.
HeartBeam CEO and founder Branislav Vajdic said: “We believe this patent will further our effort to create a dominant IP position in the area of ambulatory VECG.
“We believe that coupling AI with the highest resolution ambulatory ECG device available will have the power to deliver unprecedented diagnostic capability for patients experiencing acute cardiac symptoms, which will ultimately lead to improved care and saved lives.
“This patent will be followed by an aggressive IP development effort with PatentVest as we refine our algorithms, systems and devices.”
HeartBeam said that the newly granted patent describes a system that calculates a cardiac risk score to provide simplified diagnostic information and actionable instructions to the patient.
The system combines the recorded cardiac signals from the HeartBeam AIMIGo VECG device with the patient’s symptoms and cardiac risk factors.
It aims to replicate the decision-making process a physician uses when assessing a patient with cardiac symptoms but performed remotely in an automated manner.
HeartBeam is a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home.
Last week, the company acquired LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers.
The acquisition extends its reach in remote monitoring and detection with full ownership of an existing, advanced FDA-approved product, said HeartBeam.
